Servier has reported that sevasemten failed its first pivotal test. In GRAND CANYON, the pivotal cohort of the drug’s Phase 2 programme in Becker muscular dystrophy, 18 months of daily oral dosing produced no statistically significant benefit over placebo on the North Star Ambulatory Assessment, the trial’s primary endpoint, and the secondary endpoints were also not met. The study enrolled 175 adults with the disease. Servier said the safety and tolerability profile remained favourable.
The result contradicts the programme’s earlier signal. In the preceding CANYON study, reported in December 2024, sevasemten met its primary endpoint with a statistically significant reduction in creatine kinase, a biomarker of muscle damage, and treated patients held stable functional scores while placebo patients declined, though that functional difference was not itself statistically significant. Servier said the GRAND CANYON results are not aligned with certain observations from the earlier studies and that it is conducting a comprehensive analysis of the full dataset before presenting complete results at a later date. No detailed efficacy figures have been published.
The timing is the commercial story. Servier acquired Edgewise Therapeutics’ muscular dystrophy business in a deal announced in June 2026, paying 1.55 billion dollars upfront with up to 1.1 billion dollars more in regulatory and commercial milestones, and the transaction closed in July. The purchase was made ahead of the pivotal data, on the strength of the biomarker results, and the functional endpoint regulators required has now failed. In June 2025 the FDA had told Edgewise that the CANYON data alone were insufficient for accelerated approval while endorsing GRAND CANYON as a single adequate study to support registration, which makes this miss the decisive one for Becker muscular dystrophy, a condition with no approved treatment.
What remains open is Duchenne. Sevasemten, a fast skeletal myosin inhibitor designed to protect dystrophin deficient muscle from contraction induced damage, is also in a Phase 2 trial in Duchenne muscular dystrophy, a more severe form of the disease. Servier has not said whether the Becker result changes that programme, and has not announced any write down or restructuring tied to the acquisition.